Medical Apps CE marking
CE marking indicates that your product has been assessed to meet EU safety, health and environmental protection requirements and that it can be freely traded within the European Economic Area (EU + EFTA countries). It is valid for products developed both inside and outside the EEA. It is required for all products, including software/apps, that fall under the definition of a medical device.

When users download and install an app with a medical purpose – diagnose, treat, monitor or prevent a disease – they expect that the software will be safe and work properly. If your mobile health app falls under the EU definition of a medical device, it must bear the CE mark to be placed in the EU market. 

PATHWAY TO CE MARKING for Medical Apps and Medical Software

Product life-cycle assessment & risk classification;

Gap analysis of technical documentation and identification of conformity assessment procedures;

Regulatory and Quality Assurance Strategy Report;

Guidance on successful implementation and maintenance of QMS ISO 13485;

Software testing and validation;

Compilation of Technical File/Design Dossier (a technical file must be maintained by the manufacturer, or EU representative if the manufacturer is outside the EU, and be available to the national authorities for inspection and control purposes. The technical file contains all information that is necessary to demonstrate the conformity of the product to the applicable requirements.);

Review of e-labelling and e-IFU;

Identify whether independent assessment of your conformity is required by a Notified Body;

Pass successfully trough NB assessment to obtain a CE Certificate;

Get your CE marking;

 Issue a CE Declaration of Conformity;

 Appoint an European Authorized Representative (if applicable);

 Register with local authorities (if applicable);

 Check that no other national requirements exist in the country where the product is to be sold.

You may now place your app in the entire European market.

further
reading

cosmetic products

P-Cymene may soon be banned from cosmetics

Ingredient: P-CYMENE

Date of publication: 10/1/2025

P-cymene may be banned from cosmetics as its proposed classification as Reprotoxic 1B is under review and is expected to be approved.

Read More »
cosmetic products

SCCS Preliminary Opinion on Benzophenone-1 (BP-1)

Ingredient: BENZOPHENONE-1

Date of publication: 25/10/2024

On October 25 2024, the Scientific Committee on Consumer Safety (SCCS) could not conclude on the safety of UV absorber Benzophenone-1 (BP-1) due to insufficient data. The deadline for comments is set to January 13, 2025.

Read More »
cosmetic products

UK – OPSS Releases Statuatory Instrument on CMR Substances and Kojic Acid

Ingredients: CMR SUBSTANCES AND KOJIC ACID

Date of publication: 17/12/2024

On December 17, 2024, UK’s Office for Product Safety and Standards (OPSS) published the Cosmetic Products (Restriction of Chemical Substances) (No.2) Regulations 2024′ adding 64 substances classified as Carcinogenic, Mutagenic, or Reprotoxic (CMR) to Annex II of the UK Cosmetics Regulation (UKCR) and Kojic Acid to Annex III of the UKCR.

Read More »
cosmetic products

SCCS Preliminary Opinion on Ethylhexyl Methoxycinnamate (EHMC)

Ingredient: ETHYLHEXYL METHOXYCINNAMATE (EHMC)

Date of publication: 25/10/2024

On October 25 2024, the Scientific Committee on Consumer Safety (SCCS) could not conclude on the safety of UV-filter Ethylhexyl Methocycinnamate (EHMC) due to insufficient data. The deadline for comments is set to January 17, 2025.

Read More »